All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
On 27th August 2018, the European Commission (EC) granted approval to Vyxeos®, 44 mg/100 mg powder for concentrate for solution for infusion for the treatment for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). This comes after the positive opinion recommending a marketing authorization for Vyxeos® was given by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).1
The EC approval for Vyxeos®, a liposomal formulation of daunorubicin plus cytarabine co-encapsulated at a molar ratio of 1:5, was based on clinical data from five studies including the pivotal phase III study (NCT01696084), which evaluated the safety and efficacy of Vyxeos® compared to cytarabine and daunorubicin (7+3) in patients with newly diagnosed t-AML and AML-MRC. The results of this pivotal study were recently published by Jeffery Lancet et al. in the Journal of Clinical Oncology.2
Three-hundred and nine patients with newly diagnosed sAML were randomly assigned 1:1 to receive Vyxeos® (n = 153, mean age = 67.8 years) or 7+3 (n = 156, mean age = 67.7) as induction and consolidation chemotherapy. The primary endpoint of the study, overall survival (OS), was met with patients in the Vyxeos® arm significantly had a longer OS compared to patients in the 7+3 arm (Median OS in the Vyxeos® and 7+3 arms: 9.56 vs 5.95 months respectively, HR = 0.69 [95% CI, 0.52–0.90], P = 0.003).2
According to the drug manufacturer’s, Jazz Pharmaceuticals, “Vyxeos® is the first chemotherapy to demonstrate an OS advantage versus the standard of care in a phase III study of older adult patients with newly diagnosed t-AML or AML-MRC”.1
Vyxeos given positive opinion by the EMA CHMP for use in high-risk acute myeloid leukemia patients
The EMA CHMP has given a positive opinion recommending marketing authorization for Vyxeos (CPX-351) for the treatment of adults with newly diagnosed...
Five new powerful weapons against AML
This quintet of new drugs is likely to reshape the therapeutic landscape of AML. patients and physicians will now have the help of several new recruits in their fight against this lethal blood cancer.
Subscribe to get the best content related to AML delivered to your inbox